Rheumatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
As a result of this unique combination of the libraries and probes, we cloned follistatin-related protein (FRP) as a novel autoantigen in systemic rheumatic diseases.
|
9786430 |
1998 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations.
|
11757036 |
2002 |
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Follistatin-related protein gene (FRP) is expressed in the synovial tissues of rheumatoid arthritis, but its polymorphisms are not associated with genetic susceptibility.
|
15638044 |
2005 |
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta.
|
16338475 |
2006 |
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Expression levels of follistatin, follistatin-like 3, and activin subunits beta(A) as well as beta(E) were investigated in chemically induced rat and human liver tumours by real-time PCR and immunohistochemistry.
|
16935389 |
2006 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that activin-induced growth inhibition is altered in FLRG-expressing breast cancer lines.
|
17671190 |
2007 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected.
|
17671190 |
2007 |
Fetal Growth Retardation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Microarray experiments identified increased expression of certain genes including leptin, soluble vascular endothelial growth factor receptor, human chorionic gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2alpha in the IUGR.
|
17240240 |
2007 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our data provide strong evidence that endogenous FLRG contributes to tumor cell proliferation through antagonizing endogenous activin effects.
|
17671190 |
2007 |
Eclampsia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia.
|
17617189 |
2007 |
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.
|
17671190 |
2007 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis.
|
22915069 |
2012 |
Diminished ovarian reserve
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR).
|
22246450 |
2012 |
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01).
|
28178680 |
2017 |
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group.
|
27623975 |
2017 |
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.
|
28178680 |
2017 |